AIM ImmunoTech is trading 5.36% down now at $0.25 after its August 10, 2026, second-quarter results showed a $3.8 million net loss and EPS of $(0.43), missing the reported consensus estimate of $(0.18).
- DURIPANC enrollment and dosing are complete; primary endpoint analysis is not expected until December 2026, with topline results anticipated in Q1 2027.
- The company’s $9.9 million cash balance provides liquidity, while investors appear focused on losses and delayed clinical catalysts.